Over-the-Counter Derivatives

Federal RegisterMay 12, 1998

Ask Donna

What actually matters in this document.

Text

COMMODITY FUTURES TRADING COMMISSION

17 CFR Parts 34 and 35

Over-the-Counter Derivatives

AGENCY: Commodity Futures Trading Commission.

ACTION: Concept Release.

-----------------------------------------------------------------------

SUMMARY: The Commodity Futures Trading Commission (``CFTC'' or

``Commission'') has been engaged in a comprehensive regulatory reform

effort designed to update the agency's oversight of both exchange and

off-exchange markets. As part of this reform effort, the Commission is

reexamining its approach to the over-the-counter (``OTC'') derivatives

market.

OTC derivatives are contracts executed outside of the regulated

exchange environment whose value depends on (or derives from) the value

of an underlying asset, reference rate, or index. They are used by

market participants to perform a wide variety of important risk

management functions. The CFTC's last major regulatory actions

involving OTC derivatives were regulatory exemptions for certain swaps

and hybrid instruments adopted in January 1993. Since that time, the

OTC derivatives market has grown dramatically in both volume and

variety of products offered and has attracted many new end-users of

varying degrees of sophistication. The market has also changed, with

new products being developed, with some products becoming more

standardized, and with systems for central execution or clearing being

studied or proposed.

The Commission hopes that the public comments filed in response to

this release will constitute an important source of relevant data and

analysis that will assist it in determining whether its current

regulatory approach continues to be appropriate or requires

modification. The Commission wishes to maintain adequate safeguards

without impairing the ability of the OTC derivatives market to continue

to grow and the ability of U.S. entities to remain competitive in the

global financial marketplace. The Commission has identified a broad

range of issues and potential approaches in order to generate detailed

analysis from commenters. The Commission urges commenters to analyze

the benefits and burdens of any potential regulatory modifications in

light of current market realities. The Commission has no preconceived

result in mind. The Commission is open both to evidence in support of

easing current restrictions and evidence indicating a need for

additional safeguards. The Commission also welcomes comment on the

extent to which certain matters are being or can be adequately

addressed through self-regulation, either alone or in conjunction with

some level of government oversight, or through the regulatory efforts

of other government agencies.

New regulatory restrictions ultimately adopted, if any, will be

adopted only after publication for additional public comment and will

be applied prospectively only. This release in no

[[Page 26115]]

way alters the current status of any instrument or transaction under

the Commodity Exchange Act. All currently applicable exemptions,

interpretations, and policy statements issued by the Commission

regarding OTC derivatives products remain in effect, and market

participants may continue to rely upon them.

DATES: Comments must be received on or before July 13, 1998.

ADDRESSES: Comments should be mailed to Jean A. Webb, Secretary,

Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st

Street, NW, Washington, D.C. 20581; transmitted by facsimile to (202)

418-5521; or transmitted electronically to {[email protected]}.

Reference should be made to ``Over-the-Counter Derivatives Concept

Release.''

FOR FURTHER INFORMATION CONTACT: I. Michael Greenberger, Director,

David M. Battan, Special Counsel, or John C. Lawton, Associate

Director, Division of Trading and Markets, Commodity Futures Trading

Commission, Three Lafayette Centre, 1155 21st Street N.W., Washington,

D.C. 20581 (202) 418-5430.

SUPPLEMENTARY INFORMATION:

I. Introduction

A. Description of Over-the-Counter Products and Markets

B. Purpose of This Release

II. Current Exemptions

A. Swaps

1. Policy Statement

2. Part 35

B. Hybrid Instruments

1. Background

2. Part 34

III. Issues for Comment

A. Background

B. Potential Changes to Current Exemptions

1. Eligible Transactions

2. Eligible Participants

3. Clearing

4. Transaction Execution Facilities

5. Registration

6. Capital

7. Internal Controls

8. Sales Practices

9. Recordkeeping

10. Reporting

C. Self-Regulation

IV. Summary of Request for Comment

I. Introduction

A. Description of Over-the-Counter Products and Markets

Over-the-counter (OTC) derivatives are contracts executed outside

of the regulated exchange environment whose value depends on (or

derives from) the value of an underlying asset, reference rate or

index.\1\ The classes of underlying assets from which a derivative

instrument may derive its value include physical commodities (e.g.,

agricultural products, metals, or petroleum), financial instruments

(e.g., debt and interest rate instruments or equity securities),

indexes (e.g., based on interest rates or securities prices), foreign

currencies, or spreads between the value of such assets.

---------------------------------------------------------------------------

\1\See Group of Thirty, Derivatives: Practices and Principles 2

(1993).

---------------------------------------------------------------------------

Like exchange-traded futures and option contracts, OTC derivatives

are used to perform a wide variety of important risk management

functions. End-users employ OTC derivatives to address risks from

volatility in interest rates, foreign exchange rates, commodity prices,

and equity prices, among other things. OTC derivative instruments also

can be used to assume price risk in order to increase investment yields

or to speculate on price changes. Participants in the OTC derivatives

market include banks, other financial service providers, commercial

corporations, insurance companies, pension funds, colleges and

universities, and governmental entities.

Use of OTC derivatives has grown at very substantial rates over the

past few years. According to the most recent market survey by the

International Swaps and Derivatives Association (``ISDA''), the

notional value of new transactions reported by ISDA members in interest

rate swaps, currency swaps, and interest rate options during the first

half of 1997 increased 46% over the previous six-month period.\2\ The

notional value of outstanding contracts in these instruments was

$28.733 trillion, up 12.9% from year-end 1996, 62.2% from year-end

1995, and 154.2% from year-end 1994.\3\ ISDA's 1996 market survey noted

that there were 633,316 outstanding contracts in these instruments as

of year-end 1996, up 47% from year-end 1995, which in turn represented

a 40.7% increase over year-end 1994.\4\ An October 1997 report by the

General Accounting Office (``GAO'') suggests that the market value of

those OTC derivatives represents ``about 3 percent'' of the notional

amount.\5\ Applying the 3% figure to the most recent ISDA number for

contracts outstanding for the first half of 1997 indicates that the

world-end market value of these OTC derivatives transactions is over

$860 billion.

---------------------------------------------------------------------------

\2\ International Swaps and Derivatives Association, Summary of

Recent Market Survey Results, ISDA Market Survey, available at

(http://www.isda.org).

\3\ Id.

\4\ Id.

\5\ General Accounting Office, GAO/GGD-98-5, OTC Derivatives:

Additional Oversight Could Reduce Costly Sales Practice Disputes 3

n.6 (1997) [hereinafter ``1997 GAO Report'']. The notional amount

represents the amount upon which payments to the parties to a

derivatives transaction are based and is the most commonly used

measure of outstanding derivatives transactions. Notional amounts

generally overstate the amount at risk and the market value of such

transactions.

---------------------------------------------------------------------------

While OTC derivatives serve important economic functions, these

products, like any complex financial instrument, can present

significant risks if misused or misunderstood by market participants. A

number of large, well publicized, financial losses over the last few

years have focused the attention of the financial services industry,

its regulators, derivatives end-users, and the general public on

potential problems and abuses in the OTC derivatives market.\6\ Many of

these losses have come to light since the last major regulatory actions

by the CFTC involving OTC derivatives, the swaps and hybrid instruments

exemptions issued in January 1993.\7\

---------------------------------------------------------------------------

\6\ See, e.g., Jerry A. Markham, Commodities Regulation: Fraud,

Manipulation & Other Claims, Section 27.05 nn. 2-22.1 (1997)

(listing 22 examples of significant losses in financial derivatives

transactions); 1997 GAO Report at 4 (stating that the GAO identified

360 substantial end-user losses). Some of these transactions

involved instruments that are not subject to the CEA.

\7\ Each of these exemptions is discussed in Part II, below.

---------------------------------------------------------------------------

B. Purpose of This Release

The Commission has been engaged in a comprehensive regulatory

reform effort designed to update the agency's oversight of both

exchange and off-exchange markets.\8\ As part of this process, the

Commission believes that it is appropriate to reexamine its regulatory

approach to the OTC derivatives market taking into account developments

since 1993. The purpose

[[Page 26116]]

of this release is to solicit comments on whether the regulatory

structure applicable to OTC derivatives under the Commission's

regulations should be modified in any way in light of recent

developments in the marketplace and to generate information and data to

assist the Commission in assessing this issue.

---------------------------------------------------------------------------

\8\ See, e.g., Proposed Rulemaking Permitting Future-Style

Margining of Commodity Options, 62 FR 66569 (Dec. 19, 1997); Concept

Release on the Denomination of Customer Funds and the Location of

Depositories, 62 FR 67841 (Dec. 30, 1997); Account Identification

for Eligible Bunched Orders, 63 FR 695 (Jan. 7, 1998); Maintenance

of Minimum Financial Requirements by Futures Commission Merchants

and Introducing Brokers, 63 FR 2188 (Jan. 14, 1998); Requests for

Exemptive, No-Action and Interpretative Letters, 63 FR 3285 (Jan.

22, 1998); Regulation of Noncompetitive Transactions Executed on or

Subject to the Rules of a Contract Market, 63 FR 3708 (Jan. 26,

1998); Distribution of Risk Disclosure Statements by Futures

Commission Merchants and Introducing Brokers, 63 FR 8566 (Feb. 20,

1998); Amendments to Minimum Financial Requirements for Futures

Commission Merchants, 63 FR 12713 (March 16, 1998); Two-Part

Documents for Commodity Pools, 63 FR 15112 (March 30, 1998); and

Trade Options on the Enumerated Agricultural Commodities, 63 FR

18821 (April 16, 1998). See also Application of FutureCom, Ltd. as a

Contract Market in Live Cattle Futures and Options, 62 FR 62566

(Nov. 24, 1997) (Internet-based trading system); Application of

Cantor Financial Futures Exchange as a Contract Market in US

Treasury Bond, Ten-Year Note, Five-Year Note and Two-Year Note

Futures Contracts, 63 FR 5505 (Feb. 3, 1998) (electronic trading

system).

---------------------------------------------------------------------------

The market has continued to grow and to evolve in the past five

years. As indicated above, volume has increased dramatically. New end-

users of varying levels of sophistication have begun to participate in

this market. Products have proliferated, with some products becoming

increasingly standardized. Systems for centralized execution and

clearing are being proposed.

The Commission hopes that the public comments filed in response to

this release will constitute an important source of relevant data and

analysis that will assist it in determining how best to maintain

adequate regulatory safeguards without impairing the ability of the OTC

derivatives market to continue to grow and the ability of U.S. entities

to remain competitive in the global financial marketplace. The

Commission has no preconceived result in mind. The Commission wishes to

draw on the knowledge and expertise of a broad spectrum of interested

parties including OTC derivatives dealers, end-users of derivatives,

other regulatory authorities, and academicians. The Commission urges

commenters to provide detail on current custom and practice in the OTC

derivatives marketplace in order to assist the Commission in gauging

the practical effect of current exemptions and potential modifications.

The Commission is open both to evidence in support or broadening

its exemptions and to evidence indicating a need for additional

safeguards. Serious consideration will be given to the views of all

interested parties before regulatory changes, if any, are proposed. In

evaluating the comments and ultimately deciding on its course of

action, the Commission will, of course, also engage in its own research

and analysis. Any proposed changes will be carefully designed to avoid

unduly burdensome or duplicative regulation that might adversely affect

the continued vitality of the market and will be published for public

comment. Moreover, any changes which impose new regulatory obligations

or restrictions will be applied prospectively only.

As this process goes forward, the Commission is mindful of the

industry's need to retain flexibility in designing new products as well

as the need for legal certainty concerning the enforceability of

agreements. Therefore, the Commission wishes to emphasize that, as was

the case with other recent concept releases, this release identifies a

broad range of issues in order to stimulate public discussion and to

elicit informed analysis. This release does not in any way alter the

current status of any instrument or transaction under the CEA. All

currently applicable exemptions, interpretations, and policy statements

issued by the Commission regarding OTC derivatives products remain in

effect, and market participants may continue to rely upon them.

II. Current Exemptions \9\

---------------------------------------------------------------------------

\9\ In addition to the exemptions discussed in the text, the CEA

excludes certain transactions. Forward contracts are excluded in

section 1a(11) of the CEA, 7 U.S.C. 1A(11). The Treasury Amendment

of the CEA excludes ``transactions in foreign currency, security

warrants, security rights, resales of installment loan contracts,

repurchase options, government securities, or mortgage and mortgage

purchase commitments, unless such transactions involve the sale

thereof for future delivery conducted on a board or trade.'' Section

2(a)(1)(A)(ii), 7 U.S.C. 2(ii). Furthermore, options on securities

or securities indexes are excluded from the Act. Section

2(a)(1)(B)(i), 7 U.S.C. 2a(i). The Commission by order has also

exempted certain transactions in energy products from the provisions

of the CEA. Exemption for Certain Contracts Involving Energy

Products, 58 FR 21286 (April 20, 1993). In addition, the Commission

has exempted certain trade options. 17 C.F.R. 32.4; Trade Options on

Enumerated Agricultural Commodities, 63 FR 18821 (April 16, 1998).

The Commission has also exempted certain transactions in which U.S.

customers establish or offset foreign currency options on the Honk

Kong Futures Exchange. Petition of the Philadelphia Stock Exchange,

Inc. for Exemptive Relief To Permit United States Customers To

Establish or Offset Positions in Certain Foreign Currency Options on

the Hong Kong Futures Exchange, Ltd. Through Registered Broker-

Dealers, 62 FR 15659 (April 2, 1997).

---------------------------------------------------------------------------

A. Swaps

1. Policy Statement

The Policy Statement was adopted by the Commission on July 21,

1989.\10\ It provides a safe harbor from regulation by the Commission

under the CEA for qualifying agreements. It addresses only swaps

settled in cash, with foreign currencies considered to be cash.\11\

---------------------------------------------------------------------------

\10\ 54 FR 30694 (July 21, 1989).

\11\ Id. at 30696.

---------------------------------------------------------------------------

To qualify for a safe harbor from regulation under the Policy

Statement, a swap agreement must have all of the following

characteristics: (1) individually tailored terms; (2) an absence of

exchange-style offset; (3) an absence of a clearing organization or

margin system; (4) undertaken in conjunction with a line of business;

and (5) not marketed to the general public.

These conditions limit the applicability of the Policy Statement

primarily to agreements entered into by institutional and commercial

entities such as corporations, commercial and investment banks, thrift

institutions, insurance companies, governments and government-sponsored

or -chartered entities. The Commission indicated however, that the

restrictions did not ``preclude dealer transactions in swaps undertaken

in conjunction with a line of business, including financial

intermediation services.'' \12\ Moreover, the restrictions reflect the

Commission's understanding that qualifying transactions will be entered

into with the expectation of performance by the counterparties, will be

bilaterally negotiated as to material economic terms based upon

individualized credit determinations, and will be documented by the

parties in an agreement (or series of agreements) that is not

standardized.\13\ The restrictions are not intended to prevent the use

of master agreements between two counterparties, provided that the

material terms of the master agreement and the transaction

specifications are individually tailored by the parties.\14\

---------------------------------------------------------------------------

\12\ Id. at 30697.

\13\ Id at 30696-97.

\14\ See id. at 30696 n. 17.

---------------------------------------------------------------------------

2. Part 35

The Futures Trading Practices Act of 1992 (``1992 Act'') \15\ added

subsections (c) and (d) to section 4 of the Act. Section 4(c)(1) \16\

authorizes the Commission, by rule, regulation or order, to exempt any

agreement, contract or transaction, or class thereof from the exchange-

trading requirements of Section 4(a) or any other requirement of the

Act other than Section 2(a)(1)(B). Section 4(c)(2) \17\ provides that

the Commission may not grant any exemption unless the Commission

determines that the transaction will be entered into solely between

``appropriate persons.'' \18\ that the exchange trading requirements of

Section 4(a) should not be applied, that the agreement, contract or

transaction in question will not have a material adverse effect on the

ability of the Commission or any contract market to discharge its

regulatory or self-regulatory duties under the Act, and that the

exemption would be consistent with the public interest and the purposes

of the Act.

---------------------------------------------------------------------------

\15\ Pub. L. No. 102-546 (1992), 106 Stat 3590, 3629.

\16\ 7 U.S.C. 6(c)(1).

\17\ 7 U.S.C. 6(c)(2).

\18\ 7 U.S.C. 6(c)(3).

---------------------------------------------------------------------------

The Commission may grant exemptions ``either unconditionally or on

stated terms or conditions.'' \19\ Thus,

[[Page 26117]]

Section 4(c) gives the Commission the authority to tailor its

regulatory program to fit the realities of the marketplace and the

needs of market participants.

---------------------------------------------------------------------------

\19\ 7 U.S.C. 6(c)(1). Section 4(d), 7 U.S.C. 6(d), provides

that

[t]he granting of an exemption under this section shall not

affect the authority of the Commission under any other provision of

the Act to conduct investigations in order to determine compliance

with the requirements or conditions of such exemption or to take

enforcement action for any violation of any provision of this Act or

any rule, regulation or order thereunder caused by failure to comply

with or satisfy such conditions or requirements.

---------------------------------------------------------------------------

Part 35 of the Commission's regulations exempts swap agreements

meeting specified criteria from the provisions of the CEA and the

Commission's regulations promulgated thereunder except for the

following: Section 2(a)(1)(B) of the CEA; \20\ the antifraud provisions

set forth in Sections 4b and 4o of the CEA \21\ and Commission Rule

32.9; \22\ and the antimanipulation provisions set forth in Sections

6(c) and 9(a)(2) of the CEA.\23\ The Part 35 swap exemption is

retroactive and effective as of October 23, 1974, the date of enactment

of the Commodity Futures Trading Commission at of 1974.\24\ Part 35 was

promulgated under authority granted to the Commission by Section 4(c)

of the Act.\25\

---------------------------------------------------------------------------

\20\ 7 U.S.C. 2a. Section 2(a)(1)(B) of the Act establishes the

respective jurisdiction of the CFTC and of the SEC over different

instruments and restricts or prohibits certain types of securities

futures.

\21\ 7 U.S.C. 6b and 6o.

\22\ Regulation 32.9, 17 CFR 32.9, prohibits fraud in connection

with commodity options transactions.

\23\ 7 U.S.C. 9 and 13(a)(2).

\24\ Pub. L. No. 93-463 (1974), 88 Stat. 1389. See Commission

Regulation 35.1(a) and Exemption for Certain Swap Agreements, 58 FR

5587 at 5588 (January 22, 1993) (adopting Part 35 Rules).

\25\ In issuing the swap exemption, the Commission also acted

pursuant to its authority to regulate options under Section 4c(b) of

the CEA, 7 U.S.C. 6c(b). See Exemption for Certain Swap Agreements,

58 FR 5587 at 5589 (Jan. 22, 1993).

---------------------------------------------------------------------------

To be eligible for exemptive treatment under Part 35, an agreement:

(1) must be a swap agreement as defined in Regulation 35.1(b)(1); (2)

must be entered into solely between eligible swap participants; (3)

must not be a part of a fungible class of agreements that are

standardized as to their material economic terms; (4) must include as a

material consideration the creditworthiness of a party with an

obligation under the agreement; and (5) must not be entered into and

traded on or through a multilateral transaction execution facility.

These criteria were designed to assure that the exempted swaps

agreements met the requirements set forth by Congress in Section 4(c)

of the CEA and ``to promote domestic and international market

stability, reduce market and liquidity risks in financial markets,

including those markets (such as futures exchanges) linked to swap

markets and eliminate a potential source of systemic risk.'' \26\

---------------------------------------------------------------------------

\26\ Id. at 5588.

---------------------------------------------------------------------------

The definition of ``swap agreement'' provided in Regulation

35.1(b)(1) is as follows:

Swap agreement means: (i) An agreement (including terms and

conditions incorporated by reference therein) which is a rate swap

agreement, basis swap, forward rate agreement, commodity swap,

interest rate option, forward foreign exchange agreement, rate cap

agreement, rate floor agreement, rate collar agreement, currency

swap agreement, cross-currency rate swap agreement, currency option,

any other similar agreement (including any option to enter into any

of the foregoing); (ii) Any combination of the foregoing; or (iii) A

master agreement for any of the foregoing together with all

supplements thereto.

This definition is the same as the definition of swap agreement set

forth in Section 4(c)(5)(B) of the CEA.\27\

---------------------------------------------------------------------------

\27\ See id. at 5589.

---------------------------------------------------------------------------

Regulation 35.1(b)(2) defines ``eligible swap participant'' as

follows:

(i) A bank or trust company (acting on its own behalf or on

behalf of another eligible swap participant);

(ii) A savings association or credit union;

(iii) An insurance company;

(iv) An investment company subject to regulation under the

Investment Company Act of 1940 . . . or a foreign person performing

a similar role or function subject as such to foreign regulation,

provided that such investment company or foreign person is not

formed solely for the specific purpose of constituting an eligible

swap participant;

(v) A commodity pool formed and operated by a person subject to

regulation under the Act or a foreign person performing a similar

role or function subject as such to foreign regulation, provided

that such commodity pool or foreign person is not formed solely for

the specific purpose of constituting an eligible swap participant

and has total assets exceeding $5,000,000;

(vi) A corporation, partnership, proprietorship, organization,

trust, or other entity not formed solely for the specific purpose of

constituting an eligible swap participant (A) which has total assets

exceeding $10,000,000; or (B) the obligations of which under the

swap agreement are guaranteed or otherwise supported by a letter of

credit * * * or other agreement by any such entity referenced in

this subsection (vi)(A) * * * or * * * in paragraph (i), (ii),

(iii), (iv), (v), (vi) or (viii) of this section; or (C) which has a

net worth of $1,000,000 and enters into the swap agreement in

connection with * * * its business; or which has a net worth of

$1,000,000 and enters into the swap agreement to manage the risk of

an asset or liability owned or incurred in the conduct of its

business or reasonably likely to be owned or incurred in * * * its

business;

(vii) An employee benefit plan subject to the Employee

Retirement Income Security Act of 1974 or a foreign person

performing a similar role or function subject as such to foreign

regulation with total assets exceeding $5,000,000, or whose

investment decisions are made by a bank, trust company, insurance

company, investment adviser subject to regulation under the

Investment Advisers Act of 1940 * * * or a commodity trading advisor

subject to regulation under the Act;

(viii) Any governmental entity (including the United States, any

state, or any foreign government) or political subdivision thereof,

or any multinational or supranational entity or any instrumentality,

agency, or department of any of the foregoing;

(ix) A broker-dealer subject to regulation under the Securities

Exchange Act of 1934 * * * or a foreign person performing a similar

role or function subject as such to foreign regulation, acting on

its own behalf or on the behalf of another eligible swap

participant: Provided, however, that if such broker-dealer is a

natural person or proprietorship, the broker-dealer must also meet

the requirements of either subsection (vi) or (xi) of this section;

(x) A futures commission merchant, floor broker, or floor trader

subject to regulation under the Act or a foreign person performing a

similar role or function subject as such to foreign regulation,

acting on its own behalf or on behalf of another eligible swap

participant: Provided, however, that if such futures commission

merchant, floor broker or floor trader is a natural person or

proprietorship, the futures commission merchant, floor broker or

floor trader must also meet the requirements of subsection (vi) or

(xi) of this section; or

(xi) Any natural person with total assets exceeding at least

$10,000,000.

The definition of ``eligible swap participant'' in Regulation

35.1(b)(2) is based on the list of appropriate persons set forth in

Section 4(c)(3)(A)-(J) of the CEA. However, the Commission, relying on

authority provided in Section 4(c)(3)(K) of the CEA, adjusted those

definitions when it adopted Part 35. These adjustments reflected the

international character of the swaps market by assuring that both

foreign and United States entities could quality for treatment as

eligible swap participants. In addition, the Commission raised the

threshold for the net worth or total asset test that must be met by

certain eligible swap participants. It applied this test as an

indication of a swap participant's financial sophistication and

background.\28\ The Commission indicated its belief that the definition

of ``eligible swap participant,'' as adopted, would not adversely

affect the swap market as it then existed.\29\

---------------------------------------------------------------------------

\28\ See id. at 5589-90.

\29\ See id. at 5590.

---------------------------------------------------------------------------

The remaining conditions that must be satisfied by swap agreements

in order

[[Page 26118]]

to qualify for the Part 35 exemption are meant, among other goals, to

assure that the exemption does not permit the establishment of an

unregulated exchange-like market in swaps.\30\ These conditions require

that the creditworthiness of any party having an obligation under the

swap agreement must be a material consideration in entering into the

agreement and prohibit a swap that is part of a fungible class of

agreements, standardized as to their material economic terms, or that

is entered into and traded on or through a multilateral transaction

execution facility from qualifying for the Part 35 exemption. The

Commission has made clear that the Part 35 exemption does not extend to

transactions that are subject to a clearing system where the credit

risk of individual counterparties to each other is effectively

eliminated.\31\

---------------------------------------------------------------------------

\30\ See id. at 5590-91.

\31\ See id. at 5591.

---------------------------------------------------------------------------

These conditions do not prevent parties who wish to rely on the

Part 35 exemption from undertaking bilateral collateral or margining

arrangements nor from applying bilateral or multiparty netting

arrangements to their transactions, provided however that, in the case

of multilateral netting arrangements, the underlying gross obligations

among the parties are not extinguished until all netted obligations are

fully performed.\32\ Nor is the Part 35 restriction on multilateral

transaction execution facilities meant to preclude parties who engage

in negotiated, bilateral transactions from using computer or other

electronic facilities to communicate simultaneously with other

participants, so long as they do not use such facilities to enter

orders or execute transactions.\33\

---------------------------------------------------------------------------

\32\ See id.

\33\ See id.

---------------------------------------------------------------------------

Similarly, standardization of terms that are not material economic

terms does not necessarily prevent an agreement from qualifying for an

exemption under Part 35, provided that the material economic terms of

the swap agreement remain subject to individual negotiation by the

parties.\34\ In this respect, the Commission has explained that:

\34\ See id. at 5590.

---------------------------------------------------------------------------

[T]he phrase ``material economic terms'' is intended to

encompass terms that define the rights and obligations of the

parties under the swap agreement, and that as a result, may affect

the value of the swap at origination or thereafter. Examples of such

terms may include notional amount, amortization, maturity, payment

dates, fixed and floating rates or prices (including method by which

such rates or prices may be determined), payment computation

methodologies, and any rights to adjust any of the foregoing.\35\

---------------------------------------------------------------------------

\35\ Id. at 5590 n. 24.

---------------------------------------------------------------------------

B. Hybrid Instruments

1. Background

In 1989, the Commission recognized that certain instruments

combined characteristics of securities or bank deposits with

characteristics of futures or options and wished to exclude from CEA

regulation those hybrid instruments whose commodity-dependent value was

less than their commodity-independent value. The Commission issued a

Statutory Interpretation Concerning Certain Hybrid Instruments

(``Interpretation'') \36\ which excluded from regulation under the CEA

and CFTC regulations debt securities within the meaning of Section 2(1)

of the Securities Act of 1933 and time deposits within the meaning of

12 CFR Section 204.2(c)(1) that had the following characteristics: (1)

indexation to a commodity on no more than a one-to-one basis; (2) a

limited maximum loss; (3) inclusion of a significant commodity

component; (4) lack of a severable commodity component; (5) no required

delivery of a commodity by means of an instrument specified in the

rules of a designated contract market; and (6) no marketing of the

instruments as futures contracts or commodity options.\37\

---------------------------------------------------------------------------

\36\ 54 FR 1139 (January 11, 1989).

\37\ Id.

---------------------------------------------------------------------------

Later in 1989, the Commission adopted Part 34, which exempted

certain hybrid instruments with commodity option components from the

CEA and from the Commission's regulations.\38\ While Part 34 expanded

the category of hybrid instruments that were considered to be outside

of the CEA and the Commission's regulations, the Commission explicitly

stated that it intended not ``to address the entire universe of hybrid

instruments in the proposed rules, but rather to establish an exemptive

framework'' that would apply to certain instruments in which issuers

had expressed an interest to that point.\39\ In 1990, the Commission

issued a revised Interpretation designed to conform the

Interpretation's treatment of hybrids with the treatment of hybrids in

Part 34.\40\ The revised Interpretation expanded the class of

securities and depository accounts eligible as hybrid instruments and

expanded the class of institutions eligible to transact in hybrids.

---------------------------------------------------------------------------

\38\ 54 FR 30684 (July 21, 1989).

\39\ Id.

\40\ 55 FR 13582 (April 11, 1990).

---------------------------------------------------------------------------

Congress included a provision in the 1992 Act permitting the

Commission to exempt any transaction from all provisions of the CEA

except Section 2(a)(1)(B). Using this new authority contained in

Section 4(c) of the CEA, the CFTC substantially modified the Part 34

regulations to exempt certain hybrids (including, for the first time,

hybrid instruments with futures-like components) from most provisions

of the CEA and from the Commission's regulations.

2. Part 34

A hybrid instrument is defined in Part 34 of the Commission's

regulations as an equity security, a debt security, or a depository

instrument with at least one commodity-dependent component that has a

payment feature similar to that of a commodity futures contract, a

commodity option contract or a combination thereof.\41\ Part 34 exempts

such hybrids, and those transacting in and/or providing advice or other

services with respect to such hybrids, from all provisions of the CEA

except Section 2(a)(1)(B) of the CEA, provided that a number of

conditions are met.\42\ The conditions include: (1) a requirement that

the issuer must receive full payment of the hybrid's purchase price;

\43\ (2) a prohibition on requiring additional out-of-pocket payments

to the issuer during the hybrid's life or at its maturity; \44\ (3) a

prohibition on marketing the instrument as a futures contract or

commodity option; \45\ (4) a prohibition on settlement by delivery of

an instrument specified as a delivery instrument in the rules of a

designated contract market; \46\ (5) a requirement that the hybrid be

initially sold or issued subject to federal or state securities or

banking laws to persons permitted thereunder to purchase the

instrument; \47\ and (6) a requirement that the sum of the values of

the commodity-dependent components of a hybrid instrument be less than

the value of the commodity-independent components.\48\

---------------------------------------------------------------------------

\41\ 17 CFR 34.2(a) (1997).

\42\ 17 CFR 34.3(a) (1997).

\43\ 17 CFR 34.3(a)(3)(i) (1997).

\44\ Id.

\45\ 17 CFR 34.3(a)(3)(ii) (1997).

\46\ 17 CFR 34.3(a)(3)(iii) (1997).

\47\ 17 CFR 34.3(a)(4) (1997).

\48\ 17 CFR 34.3(a)(2) (1997).

---------------------------------------------------------------------------

In imposing the first two conditions of Part 34's exemptions--the

requirement that the issuer of a hybrid instrument receive full payment

of the hybrid's purchase price and the ban on out-of-pocket payments

from a hybrid purchaser or holder to the instrument's issuer--the

Commission sought to limit the possible losses due to the

[[Page 26119]]

commodity-dependent components of a hybrid instrument, reasoning that

an instrument permitting the accrual of losses in excess of the face

value of such instrument is more akin to a position in a commodity

derivative than to a debt, equity, or depository instrument.\49\ The

third condition outlined above, a limitation on marketing the

instrument as a futures contract or a commodity option, was intended to

prevent purveyors of hybrid instruments from misleading investors as to

the nature, legal status and form of regulatory supervision to which

such instruments are subject.\50\ The Commission did not want potential

buyers to believe that hybrids were subject to the full protections of

the CEA.

---------------------------------------------------------------------------

\49\ Regulation of Hybrid Instruments, 58 FR 5580 at 5585

(January 22, 1993) (promulgating current Part 34 Rules).

\50\ Regulation of Hybrid Instruments, 54 FR 1128 at 1135

(January 11, 1989) (proposing original Part 34 Rules).

---------------------------------------------------------------------------

The fourth condition noted above, a prohibition on settlement by a

contract market delivery instrument, was designed to guard against

interference with deliverable supplies for settlement of exchange-

traded futures or options contracts.\51\ In adopting the fifth

condition, a limitation on persons permitted to purchase an instrument,

the Commission was seeking both to address customer protection concerns

and Congress's concern, as embodied in Section 4(c)(2)(B)(i) of the

CEA,\52\ that only transactions entered into between appropriate

persons may be exempted from the CEA.\53\

---------------------------------------------------------------------------

\51\ 58 FR 5580 at 5582.

\52\ 7 U.S.C. 6(c)(2)(B)(i).

\53\ 58 FR 5580 at 5585.

---------------------------------------------------------------------------

This sixth requirement is referred to as the ``predominance test.''

\54\ It was designed in response to authorization granted by Congress

in Section 4(c)(5)(A) of the CEA for the Commission to exempt hybrids,

which were predominantly securities or depository instruments. The

predominance test starts from the premise that hybrid instruments can

be viewed as a combination of simpler instruments, the payments on

which can be viewed as either commodity-independent or commodity-

dependent. The payments on a hybrid's commodity-independent component

are not indexed or calculated by reference to the price of an

underlying commodity, including any index, spread or basket of

commodities; the payments on a hybrid's commodity-dependent component

are so indexed or referenced.

---------------------------------------------------------------------------

\54\ 17 CFR 34.3(a)(2) (1997).

---------------------------------------------------------------------------

For a hybrid instrument to be exempted by Part 34, the present

value of the returns associated with the commodity-independent

component of an instrument (including any return of principal) must be

greater than the ``commodity-dependent value'' of the instrument. In

order to calculate the commodity-dependent value of a hybrid, Part 34

conceptually decomposes a hybrid's commodity-dependent portion into

options. The absolute values of the premiums of all implicit options

that are at- or out-of-the-money are summed to arrive at the commodity-

dependent value of the hybrid instrument.\55\ These values are

calculated as of the time of issuance of the hybrid instrument.\56\

---------------------------------------------------------------------------

\55\ More specifically, the absolute net value of all put option

premiums with strike prices less than or equal to the reference

price would be added to the absolute net value of all call option

premiums with strike prices greater than or equal to the reference

price. 58 FR 5580 at 5584. ``Reference price'' is defined in

Regulation 34.2(g), 17 CFR 34.2(g), ``as the nearest current spot or

forward price at which a commodity-dependent payment becomes non-

zero, or in the case where two potential reference prices exist, the

price that results in the greatest commodity-dependent value.''

\56\ 58 FR 5580 at 5584-85.

---------------------------------------------------------------------------

III. Issues for Comment

A. Background

As the foregoing discussion indicates, the Commission has

recognized that differences between exchange-traded markets and the OTC

derivatives market warrant differences in regulatory treatment.

Pursuant to the exemptions, activity in the OTC derivatives market has

generally been limited to decentralized, principal-to-principal

transactions between large traders. This has significant regulatory

implications.

The OTC derivatives market does not appear to perform the same

price discovery function as centralized exchange markets. Accordingly,

certain regulatory requirements related to price discovery have not

been applied to the OTC derivatives market. Thus, for example, the

Commission has not suggested that it should preapprove contract design

in the OTC derivatives market as it does for exchanges.

Similarly, the decentralization of trading in the OTC market and

the relative sophistication of the participants have meant that issues

of financial integrity and customer protection differ from exchange

markets. Thus for example, while the Commission has retained its fraud

authority for the swap market, it has not required segregation of

customer funds.

Developments in the market in the last five years, however,

indicate the need to review the current exemptions. As mentioned above,

new end-users have entered the market, new products have been

developed, some products have become more standardized, and systems for

centralized execution and clearing have been proposed. The terms and

conditions of the exemptions may need adjustment to reflect changes in

the marketplace and to facilitate continued growth and innovation.

In addition, the explosive growth in the OTC market in recent years

has been accompanied by an increase in the number and size of losses

even among large and sophisticated users which purport to be trying to

hedge price risk in the underlying cash markets. Market losses by end-

users may lead to allegations of fraud or misrepresentation after they

enter transactions they do not fully understand. Moreover, as the use

of the market has increased, entities such as pension funds and school

districts have been affected by derivatives losses in addition to

corporate shareholders.\57\

---------------------------------------------------------------------------

\57\ See 1997 GAO Report at 71.

---------------------------------------------------------------------------

Accordingly, the Commission believes it is appropriate at this time

to consider whether any modifications to the scope or the terms and

conditions of the swap and hybrid instrument exemptions are needed to

enhance the fairness, financial integrity, and efficiency of this

market. The Commission reiterates that the items listed below are

intended solely to encourage useful public comment.

The Commission urges commenters to analyze the benefits and burdens

of any potential modifications in light of current market realities. In

some areas, regulatory relief or expanded access to the market may be

warranted while in others additional safeguards may be appropriate. The

Commission is especially interested in whether modifications can be

designed to stimulate growth. This might be accomplished, for example,

by increasing legal certainty and investor confidence, thereby

attracting new market participants, or by facilitating netting and

other transactional efficiencies, thereby reducing costs. As discussed

below, the Commission also welcomes comment on the extent to which

certain matters can be adequately addressed through self-regulation.

Finally, the Commission invites other regulators to express their views

on the issues raised in this release and, in particular, how best to

achieve effective coordination among regulators. The Commission

anticipates that, where other regulators have adequate programs or

standards in place to address

[[Page 26120]]

particular areas, the Commission would defer to those regulators in

those areas.

B. Potential Changes to Current Exemptions

The exemptions provided by Part 34 and Part 35 reflect

circumstances in the relevant market at the time of their adoption. As

noted, the Commission believes that it should review these exemptions

in light of current market conditions. At the most general level, three

issues are presented with respect to these exemptions: first, what

criteria should be applied in determining whether a transaction or

instrument is eligible for exemption from the CEA; second, what should

be the scope of that exemption; and third, what conditions should be

imposed, if any, to ensure that the public interest and the policies of

the CEA are served.

1. Eligible Transactions

(a) Swaps. Part 35 sets forth certain criteria that an instrument

must meet in order to qualify for the swap exemption. These criteria

impose restrictions upon the design and execution of transactions that

distinguish the exempted swap transactions from exchange-traded

products.\58\ Given the changes in the swap market since Part 35 was

adopted, the Commission seeks comments as to whether the criteria set

forth in Part 35 continue to provide a meaningful, objective basis for

exempting transactions from provisions of the CEA and CFTC regulations.

---------------------------------------------------------------------------

\58\ CFTC, OTC Derivatives Markets and Their Regulation 78-79

(1993) (``CFTC OTC Derivatives Report'') (discussing swaps

exemption).

---------------------------------------------------------------------------

In particular, some swap agreements have become highly

standardized. The Part 35 exemption does not extend to ``fungible

agreements, standardized as to their material economic terms.'' The

Commission seeks comment on whether this part of the Part 35 criteria

provides sufficient guidance for parties involved in swaps. Parties may

have difficulty in readily assessing whether a particular transaction

qualifies for treatment under the Part 35 exemption.

In order to provide greater clarity, the Commission could adopt

additional or alternative requirements governing exempted swap

agreements. For example, the Commission could provide additional detail

concerning the concept of fungibility in this context. The Commission

could also clearly specify which terms of an agreement would be

considered to be material economic terms under Part 35.

Moreover, subject to consideration of the requirements set forth in

Sections 4(c)(1) and (c)(2) of the CEA, the Commission could consider

expanding the scope of the swap exemption so that it more clearly

applies to certain classes of transactions that exhibit some degree of

standardization. In this regard, while Section 4(c)(5)(B) authorizes

the Commission to exempt non-fungible swaps, the lack of fungibility is

not a necessary criterion under Sections 4(c)(1) or (c)(2) for

exercising exemptive authority.

Request for comment. The Commission requests comment on whether the

swaps exemption should be extended to fungible instruments and, if so,

under what circumstances. The Commission is also seeking more general

comment as to whether the swaps exemption continues to fulfill its

stated goals. In this regard, the Commission is interested in

commenters' views on what changes in the current rules may be needed to

assure that Part 35 provides legal certainty to the current market and

fulfills the statutory goals set forth in Section 4(c) of the CEA.

In particular, the Commission requests comment on the following

questions.

1. In what ways has the swap market changed since the Commission

adopted Part 35. Please address:

(a) the nature of the products;

(b) the nature of the participants, both dealers and end-users;

(c) the location of transactions;

(d) the business structure of participants (e.g., the use of

affiliates for transacting OTC derivatives);

(e) the nature of counterparty relationships;

(f) the mechanics of execution;

(g) the methods for securing obligations; and

(h) the impact of the current regulatory structure on any of the

foregoing.

2. What are the mechanisms for disseminating the prices for swap

transactions?

3. Does the swap market serve as a vehicle for price discovery in

underlying cash markets? If so, how? Please describe.

4. To what extent is the swap market used for hedging? To what

extent is it used for speculation? Please provide details.

5. Is there a potential for transactions in the swap market to be

used to manipulate commodity prices? Please explain.

6. To what degree is the swap market intermediated, i.e., to what

extent do entities

(a) act as brokers bringing end-users together?

(b) act as dealers making markets in products?

Please describe the intermediaries in the market and the extent and

nature of their activities.

7. To what extent do swap market participants act in more than one

capacity (e.g., as principal in some transactions and broker in

others)?

8. In light of current market conditions, do the existing Part 35

requirements provide reasonable, objective criteria for determining

whether particular swaps transactions are exempted under the CEA?

Should the meaning of terms such as ``fungible,'' ``material economic

terms,'' or ``material consideration'' be clarified or modified in any

way? If so, how?

9. What steps can the Commission take to promote greater legal

certainty in the swap market?

10. What types of documentation are relevant in determining whether

a particular transactions falls within the swaps exemption and/or the

Policy Statement? Should the Commission set standards in this regard?

11. If the current restrictions set forth in the Part 35

requirements negatively affect or potentially limit the OTC market or

its development in the United States, what changes would alleviate the

negative effects? Should the exemption in Part 35 be broadened in any

manner?

12. What steps, if any, can the Commission take to promote greater

efficiency in the swap market, such as for example, by facilitating

netting?

13. Are any changes in regulation relating to the design or

execution of exempted swap transactions needed to protect the interests

of end-users in the swap market? Are there changes in regulation that

would attract new end-users to the market or lead existing end-users to

increase their participation?

14. Should distinctions be made between swaps that are cash-settled

and swaps that provide for physical delivery? Please explain.

15. Should transactions in fungible instruments be permitted under

the swaps exemption?

16. To what extent should the creditworthiness of a counterparty

continue to be required to be a material consideration under the swaps

exemption? Please explain.

(b) Hybrid instruments. Part 34 was designed to exempt from

Commission regulation instruments in which the commodity futures or

option characteristics were subordinate to their characteristics as

securities and deposits. Some experienced practitioners have stated

that the definition of a hybrid instrument under Part 34 is extremely

complex and difficult to understand and to apply. Moreover, the

Commission staff has

[[Page 26121]]

recently reviewed several hybrid instruments that had very significant

commodity components yet were apparently eligible for exemption under

Part 34's technical definition.

For example, the Commission staff recently reviewed an instrument

structured as a medium-term debt instrument paying a small quarterly

coupon rate. At maturity, after subtracting out a ``factor'' reflecting

certain costs borne by the issuer, the purchaser would receive a

payment that was based on the performance of an index of futures

contract prices with no upward limit on the commodity-based return.

Moreover, the holder could lose its entire investment based on a

downward movement in the commodity index. Commission staff believed

that, under Part 34 as currently written, the instrument apparently

would be exempt from regulation under the CEA. A regulatory definition

that treats the entire principal as ``commodity independent'' despite

the fact that all of the principal on this instrument could be lost as

a direct result of movement in the commodity index warrants additional

analysis.

Another conceptual concern with the current definition is the

manner in which it assigns value to the ``commodity dependent''

component. Futures-like elements are analyzed as a combination of

offsetting at-the-money puts and calls. The sum of the absolute values

of these option premiums is the assigned value of the futures-like

component. Some observers have suggested that this test is not an

appropriate measure of the commodity dependent value. As Part 34 is

currently structured, whether or not an instrument qualifies for an

exemption depends critically on the total volatility of the commodity-

dependent portion. This creates three potential problems. First, the

technical knowledge needed to identify the commodity-dependent

volatility may be a challenge for some market participants. Second, for

two instruments that are identical except for their commodity-dependent

volatility, one might be classified as exempt while the other might

not. Indeed, if the volatility of the underlying commodity changes

through time, the classification of identical hybrid instruments issued

on different dates might be different. Thus, Part 34 may create some

undesirable ambiguity regarding which instruments qualify for an

exemption. Third, it appears to be paradoxical that short-term

instruments are more likely to be classified as exempt than long-term

instruments even though short-term instruments generally are more akin

to exchange-traded futures in many respects.

If the Commission were to modify or to clarify the predominance

test in a way that resulted in more instruments being found to have a

predominant commodity-dependent component, the Commission could

exercise its authority under Section 4(c) to exempt some or all of such

instruments subject to specified terms and conditions. As is the case

today, instruments in which the commodity-independent component was

predominant would not be subject to any such terms and conditions.

Request for comment. The Commission requests comment on the

foregoing analysis. It welcomes alternative suggestions for analyzing

hybrid instruments and for simplifying the definition of exempt hybrid

instruments.

17. In what ways has the hybrid instrument market changed since the

Commission adopted Part 34? Please address:

(a) the nature of the products;

(b) the nature of the participants, both dealers and end-users;

(c) the location of transactions;

(d) the nature of the counterparty relationships;

(e) the mechanics of execution;

(f) the methods for securing obligations; and

(g) the impact of the current regulatory structure on any of the

foregoing.

18. What are the mechanisms for disseminating prices for hybrid

instrument transactions?

19. Does the hybrid instrument market serve as a vehicle for price

discovery in underlying commodities? If so, how? Please describe.

20. To what extent is the hybrid instrument market used for

hedging? To what extent is it used for speculation? Please provide

details.

21. Is there a potential for transactions in the hybrid instrument

market to be used to manipulate commodity prices? Please explain.

22. To what degree is the hybrid instrument market intermediated,

i.e., to what extent do entities

(a) act as brokers bringing end-users together?

(b) act as dealers making markets in products?

Please describe the intermediaries in the market and the extent and

nature of their activities and the extent to which transactions in

these instruments are subject to other regulatory regimes.

23. To what extent do hybrid instrument market participants act in

more than one capacity (e.g., as a principal in some transactions and

broker in others)?

24. In light of current market conditions, do the existing Part 34

requirements provide reasonable, objective criteria for determining

whether a particular hybrid instrument performs the functions of a

futures or option or those of a security or depository instrument? Are

the criteria easily understood and applied by participants in the

market? Do they properly distinguish types of instruments? If not,

should they be changed? How?

25. What steps, if any, can the Commission take to promote greater

legal certainty in the hybrid instrument market? Please explain.

26. Should Part 34 be amended to reflect more accurately or more

simply whether commodity-dependent components predominate over

commodity-independent components?

27. Are changes in regulation relating to the design or execution

of transactions in exempted hybrid instruments needed to protect the

interests of end-users in the hybrid instrument market? Are there

changes in regulation that would attract new end-users to the market or

lead existing end-users to increase their participation?

28. Should the Commission exercise its authority to exempt any

hybrid instruments with a predominant commodity component subject to

specified terms and conditions? Please explain.

2. Eligible Participants

Section 4(c)(2) states that ``the Commission shall not grant any

exemption under'' authority granted therein ``unless the Commission

determines that . . . the agreement, contract or transaction will be

entered into solely between appropriate persons.'' Section 4(c)(3)

further states that ``the term `appropriate person' shall be limited''

to the classes of persons specifically listed therein including

``[s]uch other persons that the Commission determines to be appropriate

in light of their financial or other qualifications or the

applicability of appropriate regulatory protections.''

(a) Swaps. Part 35 currently contains a requirement that an exempt

swap agreement be between eligible swap participants, as defined in

Regulation 35.1(b)(2). The list of eligible swap participants in Part

35 is based substantially on the list of ``appropriate person'' defined

in the CEA. The Commission seeks comments as to whether the current

list of eligible swap participants should be modified in any way. The

Commission requests comment regarding whether the definition is

adversely affecting the

[[Page 26122]]

swaps market by excluding persons who should be included or,

alternatively, by including persons who are not, or should not be,

active in the current market. The Commission also seeks comment on

whether additional persons should be added and, if so, whether

additional protections would be appropriate. In either case, commenters

are asked to describe such persons and the protections they need, if

any.

Any potential change must be analyzed in light of the stated

Congressional intent that any exempted transaction must be entered into

solely by appropriate persons as defined in Section 4(c)(3)(A)-(K) of

the Act. In addition, any changes to the definition of eligible swap

participant would be considered in light of any other relevant changes

that may result from Commission follow-up to this concept release.

(b) Hybrid instruments. As discussed above, if the Commission were

to modify the predominance test under Part 34, it might also decide to

exempt certain commodity-like hybrid instruments subject to specified

terms and conditions. The Commission invites analysis on the potential

applicability of an appropriate person standard in that context.

Request for comment. 29. Should the current list of eligible swap

participants be expanded in any way? Should it be contracted in any

way? If so, how and why?

30. Are there currently eligible swap participants who would

benefit from additional protections? Are there potential swap

participants who are not currently eligible but would be appropriate

subject to additional protections? In either case, please describe the

types of persons and the types of protections.

31. Should the Commission establish a class of eligible

participants for the trading of hybrid instruments with a predominant

commodity-dependent component? If so, please describe.

32. Is it advisable to use a single definition of sophisticated

investor whenever that concept arises under the Commission's

regulations? If so, what definition should apply?

3. Clearing

Clearing of swaps is not permitted under Part 35. The Commission

expressly stated that:

The exemption does not extend to transactions that are subject

to a clearing system where the credit risk of individual members of

the system to each other in a transaction to which each is a

counterparty is effectively eliminated and replaced by a system of

mutualized risk of loss that binds members generally whether or not

they are counterparties to the original transaction.\59\

---------------------------------------------------------------------------

\59\ 54 FR 5587 at 5591.

Regulation 35.2 provides, however, that ``any person may apply to

the Commission for exemption from any of the provisions of the Act

(except 2(a)(1)(B)) for other arrangements or facilities, on such terms

and conditions as the Commission deems appropriate. * * *'' The

Commission included this proviso in order to hold open the possibility

that swap agreements cleared through an organized clearing facility

could be exempted from requirements of the Act under appropriate terms

and conditions. The Commission affirmatively stated that the proviso

``reflects the Commission's determination to encourage innovation in

developing the most efficient and effective types of systemic risk

reduction'' and that ``a clearing house system for swap agreements

could be beneficial to participants and the public generally.'' \60\

---------------------------------------------------------------------------

\60\ Id. at 5591 n.30.

---------------------------------------------------------------------------

In the years since Part 35 was issued, interest in developing

clearing mechanisms for swaps and other OTC derivatives has increased.

The Commission has had extensive discussions with several organizations

engaged in designing clearing facilities.\61\ The Commission believes

that these efforts have reached a stage where it is necessary to

consider and to formulate a program for appropriate oversight and

exemption of swaps clearing.

---------------------------------------------------------------------------

\61\ Not all the proposed arrangements have included the

mutualization of risks among members of a clearing organization. In

some cases, a single entity proposed to support the clearing

arrangements using its own assets.

---------------------------------------------------------------------------

Clearing organizations can provide many benefits to participants,

such as the reduction of counterparty credit risk, the reduction of

transaction and administrative costs, and an increase in liquidity.

They also can provide benefits to the public at large by increasing

transparency. These benefits are obtained at the cost of concentrating

risk in the clearing organization. Accordingly, a greater need may

exist for oversight of the operations of a clearing organization than

for any single participant in an uncleared market.

In the 1993 CFTC OTC Derivatives Report, the Commission stated that

the regulatory issues presented by a facility for clearing swaps

``would depend materially upon the facility's design, such as, for

example, the extent to which the construction of such a facility is

consistent with the minimum standards for netting systems recommended

by the Report of the Committee on Interbank Netting Schemes of the

Central Banks of the Group of Ten Countries (Lamfalussy Report).'' \62\

Comment is requested concerning the usefulness of the Lamfalussy

standards in this context.

---------------------------------------------------------------------------

\62\ CFTC OTC Derivatives Report at 136-37. The Lamfalussy

standards are the following:

1. Netting schemes should have a well-founded legal basis under

all relevant jurisdictions;

2. Netting scheme participants should have a clear understanding

of the impact of the particular scheme on each of the financial

risks affected by the netting process;

3. Multilateral netting systems should have clearly-defined

procedures for the management of credit risks and liquidity risks

which specify the respective responsibilities of the netting

provider and the participants. These procedures should also ensure

that all parties have both the incentives and the capabilities to

manage and contain each of the risks they bear and that limits are

placed on the maximum level of credit exposure that can be produced

by each participant.

4. Multilateral netting systems should, at a minimum, be capable

of ensuring the timely completion of daily settlements in the event

of an inability to settle by the participant with the largest single

net-debit position;

5. Multilateral netting systems should have objective and

publicly-disclosed criteria for admission which permit fair and open

access; and

6. All netting schemes should ensure the operational reliability

of technical systems and the availability of back-up facilities

capable of completing daily processing requirements.

---------------------------------------------------------------------------

The Commission has identified the following core elements that

should be addressed: the functions that an OTC derivatives clearing

facility would perform; the products it would clear; the standards it

would impose on participants; and the risk management tools it would

employ. As discussed below, the Commission invites comments on each of

these topics.

(a) Functions. An OTC derivatives clearing facility could perform a

variety of functions ranging from simple trade comparison and

recordation to netting of obligations to the guarantee of performance.

For example, the Commission notes that, in jurisdictions other than the

U.S., there may not be a clearing guarantee, or the guarantee may

attach at a time other than the initiation of the trade. The Commission

requests comment on which of these functions, if any, should be

permitted and under what circumstances.

(b) Products cleared. The definition of the term ``swap agreement''

in Regulation 35.1(b)(1) is very broad. Financial engineers are

continually designing new products that fall within that definition but

have novel characteristics. As a practical matter, the Commission

believes that any OTC derivatives clearing facility would be most

likely in the context of ``plain vanilla'' products for which prices

can be readily established and for which there is some standardization

as to

[[Page 26123]]

terms. The Commission requests comment on whether the range of products

that may be cleared through an OTC derivative clearing facility, or

their terms of settlement, should be limited in any way.

(c) Admission standards. The class of eligible swap participants

ias defined in Regulation 35.1(b)(2). There is an inherent tension

between the desire to promote open and competitive markets by allowing

access.\63\ and the desire to maintain financial integrity by imposing

admission standards. The Commission requests comment on what standards,

if any, it should establish, or permit an OTC derivatives clearing

facility to establish, for admission as a clearing participant. Comment

is also requested on whether clearing should be limited to transactions

undertaken on a principal-to-principal basis or whether agency

transactions should be included.\64\

---------------------------------------------------------------------------

\63\ See Section 15 of the Act, 7 U.S.C. 19.

\64\ Current Part 35 allows only certain eligible swap

participants to act on the behalf of another eligible swap

participant. See 17 CFR 35.1(b)(2) (1997).

---------------------------------------------------------------------------

(d) Risk management tools. An OTC derivatives clearing facility

could choose from among many potential risk management tools. These

include capital requirements for participants, reporting requirements,

position or exposure limits, collateral requirements, segregation

requirements, mark-to-market or other valuation procedures, risk

modeling programs, auditing procedures, and information-sharing

arrangements. The clearing facility could also draw upon its own

capital, its lines of credit, any guarantee funds financed by clearing

members, or other arrangements for sharing losses among participants.

The relevance of these various items would depend, of course, on the

functions the clearing facility performed and the products its cleared.

The Commission requests comment on how best to assure that a clearing

facility uses appropriate risk management tools without preventing

flexibility in the design of such tools or inhibiting the evolution of

new risk management technology.

(e) Other considerations. Permitting OTC products to be cleared may

make them more like exchange-traded products. The Commission welcomes

comment on how best to promote fair competition and even-handed

regulation in the context of the clearance of OTC derivative products.

In approving Part 35, the Commission noted that it was ``mindful of

the costs of duplicative regulation \65\ and added the proviso to

Regulation 35.2 that the Commission would consider ``the applicability

of other regulatory regimes'' in addressing petitions for further

exemptive relief relating to swaps facilities. The Commission

recognizes that existing clearing facilities that are regulated by

another federal regulatory authority because the clear products subject

to that regulator's jurisdiction may wish to develop swap clearing

facilities. The Commission requests comment on how to address this

situation.

---------------------------------------------------------------------------

\65\ 58 FR 5587 at 5591 n.30.

---------------------------------------------------------------------------

Request for comment. 33. Are any swaps currently subject to any

type of clearing function, either in the U.S. or abroad? If so, please

provide details.

34. Would permitting swap clearing facilities promote market growth

and assist U.S. participants in remaining competitive? If so, please

describe the appropriate elements of a program for the oversight of

swap clearing organizations.

35. Should there be a limit on the clearing functions permitted for

swaps?

36. Should there be a limit on the range of products that may be

cleared through a swap clearing facility?

37. Should there be standards for admission as a clearing

participant?

38. What types of risk management tools should a clearing facility

employ?

39. To what degree would cleared swaps be similar to exchange

traded products? How best can the Commisison promote fair competition

and even-handed regulation in this context?

40. How should the Commission address OTC derivative clearing

facilities that are subject to another regulatory authority by virtue

of conducting activities subject to that regulator's jurisdiction?

4. Transaction Execution Facilities

Regulation 35.2(d) provides that a swap agreement may not be

entered into or traded on or through a multilateral transaction

execution facility (``MTEF'').\66\ In the release issuing Part 35, the

Commission described an MTEF as:

\66\ 17 CFR 35.2(d) (1997).

---------------------------------------------------------------------------

[A] physical or electronic facility in which all market makers

and other participants that are members simultaneously have the

ability to execute transactions and bind both parties by accepting

offers which are made by one member and open to all members of the

facility.\67\

---------------------------------------------------------------------------

\67\58 FR 5587 at 5591.

---------------------------------------------------------------------------

The Commission specified that the MTEF limitation did not:

[P]reclude participants from engaging in privately negotiated

bilateral transactions, even where these participants use computer

or other electronic facilities, such as ``broker screens,'' to

communicate simultaneously with other participants so long as they

do not use such systems to enter orders to execute transactions.\68\

\68\ Id.

---------------------------------------------------------------------------

The Commission noted that there were no swap MTEFs in existence at

that time.\69\ Consistent with the proviso in Regulation 35.2, the

Commission invited application for appropriate exemptive relief for

such facilities as they were developed.\70\

---------------------------------------------------------------------------

\69\ Id.

\70\ Id.

---------------------------------------------------------------------------

The Commission is requesting comment on whether the regulatory

approach to execution facilities should be modified in any way.

Specifically, the Commission invites comment on whether the description

of MTEFs set forth above is sufficiently clear, whether it accurately

delineates the relevant features, and how the Commission should address

other types of entities that facilitate execution, such as market

makers or bulletin board services. The Commission recognized when it

promulgated Part 35 that MTEFs ``could provide important benefits in

terms of increased liquidity and price transparency.'' \71\ The

Commission seeks comment on whether it should permit swaps to be traded

through an MTEF or other similar facilities and, if so, what terms and

conditions should be applied. It also seeks comment on the degree to

which such trading would be similar to exchange trading and the degree

to which similar safeguards are needed. As in the case of clearing

facilities, the Commission is mindful of the need to promote fair

competition between and even-handed regulation of exchanges and the

swap market.

---------------------------------------------------------------------------

\71\ Id.

---------------------------------------------------------------------------

Part 36 of the Commission's regulations \72\ was designed to allow

reduced regulation for exchange trading limited to sophisticated

traders. It was intended to ``permit * * * exchange-traded products

greater flexibility in competing with foreign exchange-traded products

and with both foreign and domestic over-the-counter transactions while

maintaining basic customer protection, financial integrity and other

protections associated with trading in an exchange environment.'' \73\

No contract market has applied for exemption under Part 36. An analysis

of the perceived strengths and weaknesses of Part 36 may be a useful

starting point in determining an appropriate regulatory regime for

execution facilities. Accordingly, the Commission requests comment on

whether elements

[[Page 26124]]

of Part 36 should be applicable to execution facilities. Proposals for

modification of Part 36 are welcome.

---------------------------------------------------------------------------

\72\ 17 CFR 36.1-36.9 (1997).

\73\ Section 4(c) Contract Market Transactions, 60 FR 51323

(Oct. 2, 1995).

---------------------------------------------------------------------------

Request for comment. 41. Should the definition of MTEF be changed

in any way to provide more clarity?

42. Are MTEFs or other types of execution facilities currently

being used for swap trading, either in the U.S. or abroad? If so,

please provide details.

43. What terms and conditions, if any, should be applied to

execution facilities? Please address potential competitive effects on

current exchange trading and the degree to which similar requirements

should be made applicable. Please also address the strengths and

weaknesses of current Part 36 for this purpose.

5. Registration

Registration has been called ``the kingpin in [the CEA's] statutory

machinery, giving the Commission the information about participants in

commodity trading which it so vitally requires to carry out its other

statutory functions of monitoring and enforcing the Act.\74\

Registration identifies participants in the markets and allows for a

``screening'' process by requiring applicants to meet fitness

standards. Registration may also facilitate enforcement of fraud

prohibitions. In addition, the requirement to register may trigger

other standards and obligations for registrants under the CEA and

Commission rules.\75\ Part 34 and Part 35 of the Commission's

regulations currently exempt parties from the registration requirements

of the Act with respect to qualifying transactions.

---------------------------------------------------------------------------

\74\ Commodity Futures Trading Commission v. British American

Commodity Options Corp., 560 F.2d 135 at 139-40 (2d Cir. 1977) cert.

denied, 438 U.S. 905 (1978).

\75\ See, e.g., Sections 8a(2) and 8a(3) of the Act (statutory

disqualification) and Regulation 1.12 (requirement that registered

futures commission merchants (``FCMs'') and registered introducing

brokers (``IBs''), or any person who files an application to be so

registered, notify the Commission if its capital falls below minimum

capital requirements); Regulation 1.15 (risk assessment reporting

for registered FCMs); Regulation 1.17 (minimum capital requirements

for registered FCMs and registered IBs); Regulation 4.21

(requirement that commodity pool operators (``CPOs'') who are

registered or required to be registered deliver a disclosure

document to clients or potential clients). Other regulations,

however, may be applicable to parties whether or not they are

registered or required to be registered. See, e.g., Part 189 (large

trader reporting requirements).

---------------------------------------------------------------------------

The Commission seeks comment on whether registration requirements

for dealers or intermediaries would be useful or necessary for the

Commission in its oversight of the OTC derivatives market. Registration

would identify key players in the OTC derivatives markets but would not

necessarily trigger the full range of regulations applicable to

registered persons involved in exchange-traded futures and options.

Instead it could be related to separate and limited OTC derivatives

market regulations. Alternatively, the Commission seeks comment on

whether it would be appropriate to adopt a notice filing, requiring

parties involved in certain activities within the OTC derivatives

markets to identify themselves to the Commission.

In addressing this issue, commenters should consider, among other

things, whether a distinction should be made between swaps and hybrid

instruments. Comment also would be useful on whether it would be

sufficient that a person is registered or regulated by another federal

agency so that the Commission should waive any registration

requirements for such persons with respect to OTC derivatives

transactions.

Differences between the OTC derivative market and exchange-traded

futures and option markets may affect the need for registration in the

context of OTC derivatives trading. For example, since swap

transactions occur among institutional participants who bilaterally

negotiate an agreement, there may be reduced value added in requiring

dealers or advisors to undergo fitness checks. Such institutional

participants would likely have the resources to investigate the fitness

of potential counterparties and advisors.

Request for comment. 44. What benefits might arise from requiring

registration of dealers, intermediaries, advisors, or others involved

in OTC derivative transactions? Should any requirement be in the form

of a notice filing or full registration?

45. What criteria should be used in determining the types of

transactions and the types of market participants subject to

registration requirements?

46. Should regulation by other federal agencies be a factor in

permitting an exemption from registration or notice filing?

47. What role should membership in a designated self-regulatory

organization play?

6. Capital

Capital requirements have long been considered important for

assuring a firm's ability to perform its obligations to its customers

and to its counterparties and for controlling systemic risk. The

Commission currently imposes no capital requirements on participants in

the OTC derivatives markets. Given the sophistication of the

participants, the generally principal-to-principal nature of their

relationships with one another, the fact that OTC derivatives dealers

typically do not hold customer's funds in an agency relationship (in

contrast to futures commission merchants or broker-dealers), and the

applicability of other regulatory capital standards to many market

participants, capital requirements may be unnecessary.

The Commission seeks to explore whether regulatory capital might

serve a useful function in the context of the OTC derivatives markets.

For example, regulatory capital might provide an OTC derivatives

dealer's counterparties with independent assurance of the

creditworthiness of the dealer or might prevent the dealer from

assuming excessive leverage. Capital requirements might also serve the

function of providing early warning of financial difficulties.

Request for comment. 48. Are any capital requirements for OTC

derivatives dealers needed? Why? What benefits would they provide to

the market? What burdens would they impose?

49. Should any reporting or disclosure requirements be established

for dealers as an alternative to capital requirements in order to

permit counterparties to evaluate their creditworthiness adequately?

Please explain.

50. Do ratings by nationally recognized statistical rating

organizations fulfill the function of assuring end-user counterparties

of the creditworthiness of OTC derivatives dealers?

7. Internal Controls

The importance of internal controls for financial services firms

generally and for derivatives dealers in particular is widely

recognized.\76\ The Commission has long required information concerning

risk management and internal control systems from FCMs, as well as

prompt reporting of any material inadequacies in such systems.\77\

Close attention to risk management and internal control systems may be

especially important in an environment where capital standards (whether

imposed by regulators or internally) are reduced and are based on the

results of internal value-at-risk models and calculations rather than

on more standardized ``haircuts.'' While a

[[Page 26125]]

complete discussion of internal control programs is beyond the scope of

this release, the following elements of such a program are generally

considered particularly important: effective models for measuring

market and credit risk exposure; careful procedures for continuously

validating those models, including rigorous backtesting and stress

testing; netting arrangements that are enforceable in the relevant

jurisdictions (and programs to review their enforceability on a regular

basis); and a risk monitoring unit which reports directly to senior

management, is independent of the business units being monitored, and

has the necessary training and resources to accomplish its control

objectives.

---------------------------------------------------------------------------

\76\ See, e.g., DPG Framework at 13-22; IOSCO, The Implications

for Securities Regulators of the Increased use of Value at Risk

Models by Securities Firms, Section 2 (Jul. 1995); Basle Committee

on Banking Supervision, Framework for the Evaluation of Internal

Control Systems at 1 (Jan. 1998); Group of Thirty, Derivatives:

Practices and Principles at 2 (1993).

\77\ See, e.g., Regulations 1.14(a)(1)(ii); 1.15(a)(1)(ii);

1.16(e)(2).

---------------------------------------------------------------------------

Request for comment. 51. Would OTC derivatives market participants

benefit from internal control guidelines? If so, what market

participants should be covered?

52. What provisions should be included in internal control

requirements, if any?

53. How should compliance with any internal control requirements be

monitored (e.g., regular audits, periodic spot checks, required

reports)?

54. Who should be responsible for monitoring compliance with any

internal control requirements (e.g., regulatory agencies, SROs,

independent auditors)?

55. Could and should internal control standards serve as a

substitute for regulatory capital requirements?

8. Sales Practices

As noted in the Introduction, a significant number of participants

in the OTC derivatives markets have experienced large financial losses

since the Commission's last regulatory initiatives involving OTC

derivatives. The 1997 GAO Report notes that ``[s]ales practice concerns

were raised in 209, or 58 percent, of [the] losses [reviewed in the

Report] and were associated with an estimated $3.2 billion in losses.''

\78\ Size and sophistication of a market participant may not provide

meaningful protection against sales practice concerns, such as fraud.

---------------------------------------------------------------------------

\78\ 1997 GAO Report at 71.

---------------------------------------------------------------------------

The parties to OTC derivatives transactions are commonly referred

to as end-users and dealers.\79\ End-users and OTC derivatives dealers

may have differing views concerning the respective responsibilities of

the parties to an OTC derivatives transaction. According to a survey

undertaken in conjunction with the GAO Report, ``about one-half of all

end-users of plain vanilla or more complex OTC derivatives believed

that a fiduciary relationship of some sort existed in some or all

transactions between them and their dealer.'' \80\ By contrast, ``two

dealer groups issued guidance asserting that such transactions are

conducted on a principal-to-principal, or an `arm's-length,' basis

unless more specific responsibilities are agreed to in writing or

otherwise provided by law.'' \81\ These differences in view can create

problems, especially because of the extraordinary complexity of some

OTC derivatives instruments and the information disparity between a

derivatives dealer and many end-users. Therefore, comments concerning

whether there is a need for sales practice rules applicable to OTC

derivatives dealers would be useful.

---------------------------------------------------------------------------

\79\ By ``end-users'' the Commission is referring generally to

participants who use derivatives to manage financial risks and

opportunities that arise in the course of their businesses. Dealers

are distinguished from end-users by their willingness to make two-

way markets in OTC derivatives, either for end-users or for other

dealers. See however, Derivatives Policy Group, Framework for

Voluntary Oversight (Mar. 1995) (``DPG Framework'') (the Framework

was developed by a group of six major investment firms). The DPG

Framework refers to dealers as ``professional intermediaries'' and

to end-users as ``nonprofessional counterparties.'' This difference

in articulation is symptomatic of the differing views that sometimes

exist among the participants in these markets concerning their

respective roles.

\80\ 1997 GAO Report at 5.

\81\ Id. See DPG Framework at 9; and Federal Reserve Bank of New

York, Principles and Practices for Wholesale Financial Market

Transactions 1 (Aug. 17, 1995) (the Principles and Practices were

developed by a group of six financial industry trade associations in

coordination with the Federal Reserve Bank of New York).

---------------------------------------------------------------------------

In granting the Part 35 swaps exemption, the Commission retained

the applicability of its basic antifraud and antimanipulation

authority.\82\ In addition, some OTC derivatives transactions are

subject to sales practice standards administered by other financial

regulatory agencies. For example, both the Office of the Comptroller of

the Currency and the Federal Reserve Board have issued guidance

addressing sales practice issues in the context of a bank's overall

responsibilities for managing the risks of its financial activities,

including OTC derivatives.\83\

---------------------------------------------------------------------------

\82\ See 17 CFR 35.2 (1997).

\83\ See, e.g., OCC, Banking Circular 277: Risk Management of

Financial Derivatives, BC-277, 1993 WL 640326 (OCC) (Oct. 23, 1993);

OCC Bulletin, Questions and Answers Re: BCC 277, OCC 94-31, 1994 WL

194290 (OCC) (May 10, 1994); and Division of Banking Supervision and

Regulation, Board of Governors of the Federal Reserve System,

Examining Risk Management and Internal Controls for Trading

Activities of Banking Organizations, [SR 93-69 (FIS)], (Dec. 20,

1993). These are not sales practice standards in the usual sense but

bank risk management standards.

---------------------------------------------------------------------------

The Commission seeks comments concerning potential sales practice

standards for principal-to-principal transactions between dealers and

end-users. The Commission would also welcome information from

commenters concerning the volume of transactions, if any, in which

dealers act strictly as agents, rather than principals, in facilitating

transactions between two end-users and whether any specific sales

practice rules should apply to such agency transactions. Likewise, the

Commission would welcome comments on the volume of transactions in

which dealers trade directly with other dealers for their own

proprietary accounts and whether any specific sales practice rules

should apply to those dealer-to-dealer transactions.

(a) Disclosure. Traditionally, the most fundamental regulatory

protection in the area of sales practices has been the duty to disclose

risks and other material information concerning transactions to

potential customers. Disclosure concerns have often been raised with

respect to OTC derivatives transactions. For example, the DPG

Framework, in its section on counterparty relationships, states that

dealers should consider providing new end-users with ``[g]eneric [r]isk

[d]isclosure,'' which it characterizes as ``disclosure statements

generally identifying the principal risks associated with OTC

derivatives transactions and clarifying the nature of the relationship

between the [dealer] and its counterparties.'' \84\ This section of the

DPG Framework goes on to provide additional details on the nature of

the relationship to be clarified, stating the DPG's view that ``OTC

derivatives transactions are predominantly arm's-length transactions in

which each counterparty has a responsibility to review and evaluate the

terms and conditions, and the potential risks and benefits, of

prospective transactions * * *.'' \85\ However, the DPG Framework

provides no further guidance as the nature or content of the generic

risk disclosure.\86\ Comment is

[[Page 26126]]

solicited on whether risk disclosure should be required and, if so, the

nature and content of such disclosure.

---------------------------------------------------------------------------

\84\ DPG Framework at 37. The 1997 GAO Report recommends that

the CFTC and SEC establish a mechanism for determining that the DPG

firms are, in fact, following this and other sales practice

standards in the DPG Framework.

\85\ Id.

\86\ The section of the DPG Framework on risk management

controls lists five basic risks of OTC derivative transactions:

market risk, credit risk, liquidity risk, legal risk, and

operational risk. Id. at 14-15. in addition to these firm-specific

risks, the CFTC OTC Derivatives Report lists a number of potential

risks arising from OTC derivatives activities generally, including

the complexity of the derivatives marketplace, the fact that dealer

activity tends to be concentrated in a relatively small number of

large entities, the lack of transparency, and systemic risk. See

CFTC OTC Derivatives Report at 112-122. It may also be appropriate

to consider whether to require dealers to disclose to prospective

end-users other material information concerning OTC derivatives

transactions, such as the relationship of the parties, the material

terms of the contract, periodic reports of the status of the end-

user's account, information on how the value of the OTC derivatives

instrument would be affected by changes in the markets for the

underlying components, and other similar information.

---------------------------------------------------------------------------

(b) Customer information. Comment is also solicited on whether it

would be appropriate to require the dealer to obtain certain

information from the end-user. Such information might include, for

example:

net worth information;

information confirming that the end-user is within the

class of eligible participants set out in Section 35.1 of the

Commission's regulations; \87\ or

---------------------------------------------------------------------------

\87\ 17 CFR 35.1(b)(2) (1997).

---------------------------------------------------------------------------

information demonstrating that the end-user is authorized

to enter into the transaction.

(c) Other possible sales practice rules. Potential sales practice

rules might also include provisions requiring dealers to supervise

sales personnel and other employees responsible for handling the

accounts of end-user customers. One element of such supervision might

be to ensure that sales personnel are properly trained.

The Commission also wishes to consider what regime, if any, would

be appropriate for overseeing the implementation and enforcement of any

sales practice rules for OTC derivatives, including the costs and

benefits of alternative oversight mechanisms. In that context, the

Commission is seeking comments on: (1) the appropriate direct

regulatory role of the CFTC with respect to potential sales practice

rules; (2) the appropriate regulatory role of other financial

regulatory agencies, including the applicability of any sales practice

rules administered by other agencies and the degree of deference that

should be accorded to such rules; and (3) the appropriate sales

practice role of industry self-regulatory bodies, including the degree

of CFTC oversight necessary to assure that any industry self-regulatory

standards are properly implemented and enforced.

Request for comment. 56. Since Part 35 was adopted, has the swap

market experienced significant problems concerning fraud or sales

practice abuses? Since Part 34 was adopted, has the hybrid instrument

market experienced significant problems concerning fraud or sales

practice abuses? If so, please describe.

57. Is there a need for any sales practice rules in the OTC

derivatives market? If so, what should the rules provide, and to whom

and under what circumstances should they be applicable?

58. Is there a need for risk disclosures by OTC derivatives dealers

to end-users? If so, what risks should be disclosed?

59. Should OTC derivatives dealers be required to supplement any

required generic risk disclosure statement with additional firm- or

transaction-specific disclosures? If so, what should such disclosures

cover?

60. What kind of disclosures, if any, should dealers make to end-

users clarifying the nature of the relationship between the parties?

Should there be rules establishing duties of the OTC derivatives dealer

to its customers, and if so, what should they require?

61. What kind of disclosures, if any, should dealers make

concerning the material terms of OTC derivatives contracts, including

methods for calculating price, value, profit and loss, as well as the

amount of commissions, fees and other costs involved?

62. What other kinds of disclosures, if any, might be appropriate

concerning, for example, potential conflicts of interest, the dealer's

policies on helping end-users to unwind transactions and matters such

as the dealer's financial soundness, experience, or track record?

63. Should dealers be required to make periodic status reports to

end-users concerning the status of their OTC derivatives positions

(e.g., value, profits and losses)? If so, what kind of reports should

be required, and how often should such reports be made?

64. Should dealers be required to collect information concerning

their end-user customers? If so, what kind of information? Should

dealers be required to retain documentation in their files concerning

such information, and if so, what kind of documentation (e.g.,

confirming that particular information has been collected and reviewed

by management to assure transactions are in conformity with the end-

user's investment goals and policies)?

65. What sales practice rules, if any, should apply to transactions

where a dealer is acting as an agent or broker to facilitate a

principal-to-principal transaction between two end-users? Similarly,

what sales practice rules, if any, should apply to dealer-to-dealer

transactions where both dealers are trading for their own proprietary

accounts?

66. Should dealers have to comply with different sales practice

standards in dealing with end-users having different levels of

sophistication, based, for example, or portfolio size, investment

experience, or some other measure? If so, please elaborate.

67. Should dealers be required to follow any supervision

requirements in connection with the activities of sales personnel and

other employees responsible for handling the accounts of end-user

customers? Should complex or highly leveraged transactions require

prior approval by senior management of the dealer?

68. What is the appropriate regime for formulating and overseeing

the implementation and enforcement of possible sales practices rules,

including the appropriate roles of the Commission, other financial

regulators and industry self-regulatory bodies?

9. Recordkeeping

The Commission has not required any recordkeeping requirements for

OTC derivatives dealers or other OTC market participants. Having

retained authority over fraudulent and manipulative behavior in the OTC

derivative market, the Commission wishes comment on whether some

recordkeeping requirements would facilitate its exercise of that

authority. Provisions requiring the retention of written records of

transactions with counterparties, for example, might be considered. The

Commission requests comment on whether there should be specific

recordkeeping requirements for transactions in the OTC derivatives

markets and, if so, what types of records should be kept and by whom.

Request for comment. 69. Are recordkeeping requirements for

participants in the OTC derivatives markets needed? If so, what records

should be required? Who should be required to keep them?

10. Reporting

The Commission currently does not impose reporting requirements on

OTC derivatives market participants.\88\ The

[[Page 26127]]

Commission requests comment on whether specific reporting requirements

for participants in the OTC derivatives markets are needed and, if so,

what reports should be made and by whom. If the Commission were to

establish reporting requirements, it would coordinate with other

regulatory agencies and, to the extent possible, accept reports

provided to other regulatory agencies in satisfaction of the

Commission's requirements. The Commission solicits comment concerning

how these goals might best be accomplished.

---------------------------------------------------------------------------

\88\ The DPG has established voluntary reporting requirements.

See DPG Framework at 23-25. The DPG has committed to regular

periodic reporting and to respond in good faith to ad hoc requests

for additional information by the CFTC. Id. at 1. The DPG member

firms currently provide to the Commission on a quarterly basis a

report detailing for each member except Credit Suisse First Boston:

(1) a Credit-Concentration Report listing (on a ``no-names'' basis)

the top 20 OTC derivatives exposures and, for each exposure, the

internal credit rating, the industry segment, the current net

exposure, the next replacement value, the gross replacement values

(receivable and payable) and the potential additional credit

exposure (at a ten-day, 99-percent confidence interval); (2) a

Portfolio Summary listing, by credit rating category and industry

segment, the current net exposure, net replacement value, and gross

replacement values; (3) a Geographic Distribution listing, by

country, the current net exposure, the net replacement value, and

the gross replacement values; (4) a Net Revenues Report listing, by

product category and month, the net revenue; and (5) a Consolidated

Activity Report listing, by product category, the aggregate notional

amount.

---------------------------------------------------------------------------

Request for comment. 70. Should the Commission establish reporting

requirements for participants in the OTC derivatives markets? If so,

what information should be reported? By whom?

C. Self-Regulation

Having identified areas in which current exemptions might be

modified, the Commission is also interested in the views of commenters

concerning whether, and to what extent, any needed changes concerning

the oversight of the OTC derivatives market could be accomplished

through initiatives of industry bodies either voluntarily or through a

self-regulatory organization empowered to establish rules and subject

to Commission oversight. The Commission notes that several industry

organizations already exist with an interest in maintaining and

improving the integrity of the OTC derivatives marketplace. These

organizations include, among others, the Derivatives Policy Group, the

International Swaps and Derivatives Association, the Group of Thirty,

and the End-Users of Derivatives Association. Industry groups have

already issued a number of voluntary initiatives aimed at reducing

risks and promoting stability and integrity in the OTC derivatives

marketplace.\89\ The Commission is interested in exploring the extent

to which concerns described in this release might be addressed, and

adequate oversight of the OTC derivatives marketplace might be

attained, through industry bodies or through self-regulatory

organizations.

---------------------------------------------------------------------------

\89\See, e.g.: Framework for Voluntary Oversight, supra;

Principles and Practices for Wholesale Financial Market

Transactions, supra; and Global Derivatives Study Group, Group of

Thirty, Derivatives: Practices and Principles, supra.

---------------------------------------------------------------------------

Request for comment. 71. How effective are current self-regulatory

efforts? What are their strengths and weaknesses?

72. Are there particular areas among those discussed above where

self-regulation could obviate the need for government regulation?

73. Please discuss the costs and benefits of existing voluntary

versus potential mandatory self-regulatory regimes.

74. If a self-regulatory regime were adopted, what mechanism would

best assure effective oversight by the Commission?

75. How best can the Commission achieve effective coordination with

other regulators in connection with the oversight of the OTC

derivatives market?

IV. Summary of Request for Comment

Commenters are invited to discuss the broad range of concepts and

approaches described in this release. The Commission specifically

requests commenters to compare the advantages and disadvantages of the

possible changes discussed above with those of the existing regulatory

framework. In addition to responding to the specific questions

presented, the Commission encourages commenters to submit any other

relevant information or views.

Issued in Washington, D.C. this 6th day of May, 1998, by the

Commodity Futures Trading Commission.

By the Commission (Chairperson BORN, Commissioners TULL and

SPEARS; Commissioner HOLUM dissenting).

Jean A. Webb,

Secretary of the Commission.

Dissenting Remarks of Commissioner Barbara Pedersen Holum, Concept

Release, Over-the-Counter Derivatives

In Section 4(c)(1) of the Commodity Exchange Act, Congress

authorized the Commission to exempt certain transactions ``[i]n order

to promote responsible economic or financial innovation and fair

competition.'' Indeed, it appears that the dramatic growth in volume

and the products offered in the OTC derivatives market may be

attributed in part to the Commission's past exemptive action. In the

spirit of the Commission's ongoing regulatory review program, it is

appropriate to examine the continuing applicability of the existing

exemptions, focusing on the expanding economic significance of the OTC

market. However, in my judgement,the release goes beyond the scope of

regulatory review by exploring regulatory areas that may be

inapplicable to an OTC market. Accordingly, I am dissenting from the

majority's decision to issue the Concept Release on OTC Derivatives in

its current form.

Dated: May 6, 1998.

Barbara Pedersen Holum,

Commissioner.

[FR Doc. 98-12539 Filed 5-11-98; 8:45 am]

BILLING CODE 6351-01-M

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.